Ritu Baral, an analyst from TD Cowen, maintained the Hold rating on Sarepta Therapeutics. The associated price target remains the same with $17.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ritu Baral has given his Hold rating due to a combination of factors tied to Sarepta’s mixed operating profile and balanced risk‑reward. While Elevidys posted a modest first‑quarter revenue beat and overall PMO sales tracked close to expectations, quarterly declines in key PMO franchises and only slightly better‑than‑consensus gene therapy sales temper enthusiasm about near‑term growth momentum.
Ritu Baral’s rating is based on management’s reaffirmed longer‑term revenue and expense guidance, which supports the view that the current valuation fairly reflects execution prospects and pipeline optionality. With free cash flow positivity expected by the second quarter and clarity on siRNA and FSHD/DM1 catalysts still ahead, she sees no compelling reason to change stance now and therefore keeps a neutral Hold rating with an unchanged $17 price target.